Basilea Pharmaceutica AG Allschwil
SWB:PK5
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CH |
B
|
Basilea Pharmaceutica AG Allschwil
SWB:PK5
|
756.7m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
382.9B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -62 472.2% |
| 30th Percentile | 3.5% |
| Median | 10.3% |
| 70th Percentile | 16.5% |
| Max | 91.2% |
Other Profitability Ratios
Basilea Pharmaceutica AG Allschwil
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft and currently employs 143 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. The company launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Basilea Pharmaceutica AG Allschwil is 32.2%, which is above its 3-year median of 21%.
Over the last 3 years, Basilea Pharmaceutica AG Allschwil’s Operating Margin has increased from 4.3% to 32.2%. During this period, it reached a low of -5.7% on Jun 30, 2024 and a high of 37.1% on Jun 30, 2023.
